Trivitron, the Chennai-based medical technology provider has entered into an alliance with BioSystems of Spain to manufacture IVD (in-vitro diagnostic) reagents.
Under the tie-up, BioSystems will manufacture IVD reagents for Diagnostic Lab use after setting up its manufacturing facility at Trivitron's Medical Technology Park in Chennai. This is the first facility BioSystems is making outside of Spain.
The joint venture between Trivitron and BioSystems will entail Rs 40 to 50 crore in the first phase of setting up the facility at the Medical Technology Park. The plant will be set up with the help of a specialist technical expert from Spain and will operate according to the good manufacturing practices (GMP), the ISO 9001, the ISO 13485 and the European Union laws on 'In Vitro' Diagnostics Products. This facility will cater to both domestic as well as foreign markets. Products are expected to roll out by the mid of 2010. The Medical Technology Park is coming up on a 23 acre land at Sriperumbudur near Chennai in which Trivitron has already invested Rs 170 crore.
BioSystems, located in Barcelona, is one of the largest manufacturers of clinical chemistry reagents and instruments in Europe, with three decades of research and advancements in clinical chemistry, auto-immunity (immuno-fluorescence and ELISA), and Immuno-turbidimetry reagents. The company has its manufacturing facility at Barcelona and the upcoming Chennai facility will be the first facility outside of Spain for manufacturing clinical chemistry products.
Briefing on the tie-up, managing director, BioSystems, Antonio Elduque said, "With India becoming the most favourite destination in the world for healthcare, matching its infrastructure and technology with those in UK, Europe and USA, we decided to expand our operations by setting up a manufacturing facility in India. We have identified Trivitron which is creating a first-of-its-kind, world class medical technology park in Chennai. This will be the first facility outside Spain, for the manufacturing of the clinical chemistry products and production of the same is expected to commence during 2010."
Dr G S K Velu, managing director, Trivitron, said, "We are happy to be associated with BioSystems. Our focus in setting up a medical technology park in India is to manufacture medical equipment and Diagnostic Reagents in the areas of critical care, cardiac care, imaging and routine laboratory diagnostics. The manufacturing facility we are creating will be one of the largest In Vitro Diagnostics Reagents facilities in Asia catering to all the emerging markets and to the world eventually."